Hypersensitivity and Tumor Lysis Syndrome Associated with Cetuximab Treatment: Should We be Afraid?

Abstract

The majority of the chemotherapy agents in use today cause various infusion reactions, from mild flushing to life-threatening events. The frequency of the reported hypersensitivity reactions induced by cetuximab varies between 3% and 22%. It is recommended in the literature to stop the infusion and replace cetuximab with panitumumab in case of hypersensitivity reactions observed during the treatment of colon cancer. Tumor lysis syndrome (TLS) may occur in colorectal cancers with heavy tumor load. Tumor lysis syndrome may be life-threatening. In our patient with widespread bone and liver metastases, treatment continued with cetuximab as a combination therapy with irinotecan in spite of the hypersensitivity and TLS led to a complete treatment response. The complete response observed after 3 months through continued therapy in our patient may present an example supporting treatment with cetuximab in spite of severe reactions.

Keywords

Cetuximab Complete response Hypersensitivity Tumor lysis syndrome

Get full access to this article

View all access options for this article.

References

Marshall

Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer. 2006; 107(6): 1207–1218.

Erbitux [package insert]. New York, NY: Bristol Myers Squibb and Im Clone Systems; 2008.

O'Neil

B.H.

Allen

Spigel

D.R.

High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007; 25(24): 3644–3648.

Davila Gonzalez

I.D.

Salazar Saez

Moreno Rodilla

Laffond Yges

Lorente Toledano

Hypersensitivity reactions to chemotherapy drugs. Rev Fr Allergol Immunol Clin. 2000; 15: 161–181.

Lenz

H.J.

Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007; 12(5): 601–609.

Mayer

Young

Infusion reactions and their management. Gastroenterol Clin North Am. 2006; 35(4): 857–866.

Cheifetz

Mayer

Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005; 72(4): 250–256.

Scarlet

Anaphylaxis SC. J Infus Nurs. 2006; 29: 39–44.

National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). August 9, 2006. National Cancer Institute's Cancer therapy Evaluation Program Web site. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed September 9, 2007.

10.

Dillman

R.O.

Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999; 18(4): 465–471.

11.

Breslin

Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs. 2007; 11(Suppl): 37–42.

12.

VectibixR [package insert]. Thousand Oaks, CA: Amgen Incorporated; 2008.

13.

Cunningham

Humblet

Siena

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351(4): 337–345.

14.

Van Cutsem

Peeters

Siena

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25(13): 1658–1664.

15.

Saltz

L.B.

Meropol

N.J.

Loehrer

Sr Needle

M.N.

Kopit

Mayer

R.J.

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22(7): 1201–1208.

16.

Chung

C.H.

Mirakhur

Chan

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008; 358(11): 1109–1117.

17.

Jacquenet

Moneret-Vautrin

D.A.

Bihain

B.E.

Mammalian meat-induced anaphylaxis: clinical relevance of anti-galactose-alpha-1,3-galactose IgE confirmed by means of skin tests to cetuximab. J Allergy Clin Immunol. 2009; 124(3): 603–605.

18.

Nunez

Carballada

Gonzalez-Quintela

Gomez-Rial

Boquete

Vidal

Delayed mammalian meat-induced anaphylaxis due to galactose-α-1,3-galactose in 5 European patients. J Allergy Clin Immunol. 2011; 128(5): 1122–1124.

19.

Winkler

Jensen

Manzke

Schulz

Diehl

Engert

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999; 94(7): 2217–2224.

20.

van der Kolk

L.E.

Grillo-López

A.J.

Baars

J.W.

Hack

C.E.

van Oers

M.H.

Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001; 115(4): 807–811.

21.

Kimura

Sakai

Arao

Shimoyama

Tamura

Nishio

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 2007; 98(8): 1275–1280.

22.

Sampson

J.H.

Crotty

L.E.

Lee

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci USA. 2000; 97(13): 7503–7508.

23.

Tawara

Hasegawa

Sugiura

Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J Immunol. 2008; 180(4): 2294–2298.

24.

Szebeni

Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005; 216(2-3): 106–121.

25.

Chanan-Khan

Szebeni

Savay

Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol. 2003; 14(9): 1430–1437.

26.

Szebeni

Muggia

Gabizon

Barenholz

Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev. 2011; 63(12): 1020–1030.

27.

Timoney

Chung

K.Y.

Park

Trocola

Peake

Saltz

L.B.

Cetuximab use without chronic antihistamine premedication. J Clin Oncol. 2006; 24(18 suppl): Abstract 13521.

28.

Siena

Glynne-Jones

Thaler

Infusion-related reactions (IRR) associated with cetuximab plus irinotecan treatment in patients with irinotecan-resistant metastatic colorectal cancer (mCRC): findings from the MABEL study. J Clin Oncol. 2007; 25(18 suppl): Abstract 4137.

29.

Chung

C.H.

Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008; 13(6): 725–732.

30.

Langerak

River

Mitchell

Cheema

Shing

Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports. Clin Colorectal Cancer. 2009; 8(1): 49–54.

31.

Helbling

Borner

Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol. 2007; 18(5): 963–964.

32.

Nielsen

D.L.

Pfeiffer

Jensen

B.V.

Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to cetuximab. Ann Oncol. 2009; 20(4): 798.

33.

Cartwright

T.H.

Genther

Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer. Clin Colorectal Cancer. 2008; 7(3): 202–203.

34.

Gibson

T.B.

Ranganathan

Grothey

Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer. 2006; 6(1): 29–31.

35.

Saif

M.W.

Cohenuram

Role of panitumumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer. 2006; 6(2): 118–124.

36.

Chasty

R.C.

Liu-Yin

J.A.

Acute tumour lysis syndrome. Br J Hosp Med. 1993; 49(7): 488–492.

37.

Sallan

Management of acute tumor lysis syndrome. Semin Oncol. 2001; 28(2)(Suppl 5): 9–12.

38.

Boisseau

Bugat

Mahjoubi

Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11). Eur J Cancer. 1996; 32A(4): 737–738.

39.

Krishnan

D'Silva

Al-Janadi

Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma. J Clin Oncol. 2008; 26(14): 2406–2408.

40.

Cairo

M.S.

Bishop

Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004; 127(1): 3–11.

41.

Flombaum

C.D.

Metabolic emergencies in the cancer patient. Semin Oncol. 2000; 27(3): 322–334.

42.

Arrambide

Toto

R.D.

Tumor lysis syndrome. Semin Nephrol. 1993; 13(3): 273–280.

43.

Vora

Bhutani

Sharma

Raina

Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase. Ann Oncol. 2002; 13(11): 1833–1834.

44.

Pou

Saval

Vera

Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma. 2003; 44(7): 1239–1241.

45.

Ali

Ozkalemkas

Ozkan

Tumour lysis syndrome with acute renal failure during imatinib therapy. Leuk Res. 2007; 31(4): 573–574.

46.

Abou Mourad

Taher

Shamseddine

Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20. Hematol J. 2003; 4(3): 222–224.

47.

Saylor

P.J.

Reid

T.R.

Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol. 2007; 25(23): 3544–3546.

48.

Sezer

Vesole

D.H.

Singhal

Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma. 2006; 7(3): 233–235.

49.

Haroon

Yan Kwong

Cantwell

Walker

A case of cetuximab-related tumour lysis syndrome in metastatic rectal carcinoma. Clinical Kidney Journal. 2010; 3(3): 271–272.

50.

Saif

M.W.

Syrigos

Hotchkiss

Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2009; 65(1): 107–112.